Naloxone Hydrochloride Mercury Pharmaceuticals (Ireland) Ltd

Naloxone Hydrochloride, the active ingredient in Naloxone Hydrochloride Mercury Pharmaceuticals (Ireland) Ltd, is an opioid antagonist presented as a sterile injectable solution for intramuscular, intravenous, or subcutaneous use. It rapidly reverses opioid overdose and opioid‑induced respiratory depression in emergency settings.

GNH USA supplies Naloxone Hydrochloride Mercury Pharmaceuticals (Ireland) Ltd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, ensuring product integrity throughout the supply chain.

Naloxone Hydrochloride is used to counteract the effects of opioids in acute overdose situations. - Opioid overdose: rapidly restores normal breathing and consciousness in patients experiencing life‑threatening opioid toxicity. - Opioid‑induced respiratory depression: reverses suppressed respiration caused by opioid analgesics or anesthetics. - Acute opioid toxicity: provides emergency reversal of opioid effects pending further medical care.

Naloxone Hydrochloride may be associated with several adverse reactions, most of which are transient and related to its pharmacologic action.

Common Side Effects: - Injection site pain: mild tenderness at the injection site. - Nausea: feeling of sickness after administration. - Sweating: increased perspiration following opioid reversal. - Tremor: brief shaking of muscles. - Anxiety: temporary nervousness or restlessness. - Headache: mild head discomfort. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Acute withdrawal: agitation, hypertension, tachycardia, or seizures in dependent patients. - Cardiac arrhythmias: irregular heart rhythm that may need monitoring. - Pulmonary edema: fluid buildup in lungs causing breathlessness. - Severe hypotension: sudden drop in blood pressure with risk of fainting.

When using Naloxone Hydrochloride, several precautions should be observed to ensure safety and effectiveness. - Assess patient: confirm opioid overdose before administration. - Monitor vital signs: observe respiratory rate, heart rate, and blood pressure after dosing. - Use with caution in opioid‑dependent individuals: risk of precipitated withdrawal. - Avoid intrathecal use: formulation is not intended for spinal administration. - Adjust dose in pediatric patients: dosing must be determined by a qualified clinician. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Naloxone Hydrochloride can interact with other substances; awareness of significant interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Opioid agonists (e.g., morphine, fentanyl): concurrent use may diminish naloxone’s reversal effect. - Central nervous system depressants (e.g., benzodiazepines) in high doses: may mask withdrawal symptoms.

Moderate Interactions (Monitor Closely): - Monoamine oxidase inhibitors: may increase risk of hypertensive response during withdrawal. - Tricyclic antidepressants: potential for additive cardiovascular effects. - Alcohol: can exacerbate central nervous system depression after naloxone administration.